Tetrahydrouridine

四氢尿苷

Report date: 2022/06/16 16:41:45
NME

Base Information

Drug NameTetrahydrouridine
Drug Alias NameNSC-112907THU
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytidine deaminase inhibitors
TargetsCytidine deaminase
Therapy Area/IndicationsMyelodysplastic SyndromesAnemia, Sickle CellNeoplasm Metastasis +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesEpidestiny IncNovo Nordisk A/SNational Cancer Institute +[4] 
Inactive CompaniesCity Of Hope National Medical CenterUniversity Of Illinois At Chicago
Active IndicationsAnemia, Sickle CellCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsMyelodysplastic SyndromesNeoplasm MetastasisUrinary Bladder Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A